How well can biomarkers and neurofilament predict disease activity and safety in MS?

Dr Sharmilee Gnanapavan reviews the latest data on biomarkers for disease progression in MS.

Dr Sharmilee Gnanapavan has received consulting fees from Biogen Idec, Genzyme, Teva, Novartis and Neurodiem. She has also received travel support from Teva, Novartis, Genzyme, Biogen Idec, National Multiple Sclerosis Society and MS Research Australia. Dr Sharmilee Gnanapavan has received grant support from the National Multiple Sclerosis Society, Genzyme, Takeda, Roche and Merck.